Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EIGR.US
id: 452
N.D. California
Court
On October 5, 2022, Eiger (EIGR) announced that it would not seek an EUA request for peginterferon lambda after the FDA had “denied the request for a pre-EUA meeting.”

Specifically, the Company disclosed that, “citing its concerns about the conduct of the TOGETHER study, the FDA concluded that any authorization request based on the data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic.”

Investors have reasons to suspect that the Company and its Leaders violated rights of shareholders by:
  • overstating its expertise in regulatory drug development to investors.
  • fail to properly assess problems with its TOGETHER trial and determine if the trial could support the peginterferon lambda EUA. Based on these problems with the trial, the FDA was unlikely to approve the Company’s EUA.
Alleged Offence
Misleading Statements
Failure to Disclose
Negligence
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
04 October 2022
Collecting participants…

Eiger Biopharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United S...

    Ticker
    EIGR.US
    ISIN
    US28249U1051
    CIK
    1305253
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    2155 Park Boulevard, Palo Alto, CA, United States, 94306